L’hormone minéralocorticoïde aldostérone en se fixant à son récepteur, le récepteur minéralocorticoïde (RM), module la réabsorption de sodium au niveau du rein. De nombreuses étude sont rapporté l’implication du complexe aldostérone/RM dans les pathologies cardiovasculaires, sans que les voies de signalisation activées soient encore entièrement élucidées à ce jour. Ce travail de thèse se propose d’approfondir les connaissances sur les mécanismes de la signalisation cardiaque du RM à travers deux objectifs principaux i) l’identification de nouvelles cibles moléculaires du RM dans lecoeur et ii) la compréhension des effets physiopathologiques de son activation. Par une approche pharmacologique, nous avons montré que le diurétique torasémide n’est pas capable de bloquer la voie de signalisation minéralocorticoïde dans la lignée cellulaire de cardiomyocyte transfectée avec le RM,H9C2-RM+. L’étude de l’activité transcriptionnelle du RM cardiaque a concerné la majeure partie de ce travail de thèse. Par une approche gène candidat, nous avons mis en évidence que l’expression dugène codant pour le facteur de croissance du tissu conjonctif (CTGF, pour connective tissue growthfactor) est augmentée par le RM et que l’aldostérone potentialise cet effet in vivo. Nous avons pu localiser CTGF spécifiquement dans les cardiomyocytes, et une étude in vitro nous a permis d’identifier que le RM se lie au niveau d’éléments de réponse hormonale dans le promoteur du gène codant pour CTGF. Des souris surexprimant le RM humain spécifiquement dans les cardiomyocytes et traitées avec de l’aldostérone ou de la corticostérone ont permis une exploration plus large des gènesdifférentiellement exprimés par les deux ligands du RM dans le coeur. L’analyse des transcriptomes cardiaques de ces souris et de leurs contrôles montre qu’une augmentation modeste de la concentration plasmatique en aldostérone induit dans le coeur l’expression de gènes impliqués dans le cycle cellulaire comme la Cycline B1 ou sa kinase associée Cdk1 (pour Cyclin-dependent kinase 1). Nous avons montré également que l’aldostérone active la prolifération des cellules endothéliales cardiaques. / The mineralocorticoid hormone aldosterone binding its receptor, the mineralocorticoid receptor (MR),regulates the renal reabsorption of sodium. Several studies showed the involvement of the aldosterone/MR complex in cardiovascular diseases, even if the activated signalling pathways are still unclear. This thesis work has been established to increase the knowledge on the mechanisms of thecardiac signalling of MR using two main purposes i) the identification of new molecular targets of the MR in the heart and ii) the understanding of the pathophysiological effects of its activation. Apharmacological approach showed that the diuretic torasemide cannot block the mineralocorticoid signalling in the cell line cardiomyocytes transfected with MR, H9C2-MR+. The study of the MR’s cardiac transactivation activity formed the most important part of this thesis work. We demonstrated with a candidate gene approach that the MR increases the expression of the gene coding the connective tissue growth factor (CTGF) and the aldosterone increases even more this effect in vivo. We foundCTGF specifically expressed in cardiomyocytes and we identified in vitro that the MR binds tohormonal responsive elements on the promoter of the gene coding CTGF. In order to investigate the whole genes differentially expressed by the two ligands of MR in the heart, we treated mice with cardiomyocyte-targeted human MR over expression and their controls with aldosterone or corticosterone. The cardiac transcriptomic analyses show that the majority of aldosterone-regulatedgenes is involved in cell division as Cyclin B1 or Cyclin-dependent kinase 1 (Cdk1). Also, we identified that aldosterone promotes cardiac endothelial cells proliferation.

A aldosterona participa da progressão das doenças renais em modelos experimentais e ensaios clínicos. Considerando que o modelo de hipertensão renovascular 2 rins-1 clipe (2R-1C) é caracterizado pela atividade elevada do sistema renina-angiotensina-aldosterona, o objetivo desse trabalho foi avaliar o papel da aldosterona na lesão renal presente nesse modelo através do bloqueio do receptor mineralocorticóide (RM) com espironolactona. Ratos Wistar foram submetidos ao procedimento cirúrgico para colocação de um clipe de prata na artéria renal esquerda e após 2 semanas do desenvolvimento da hipertensão renovascular 2R-1C, foram divididos em 3 grupos sendo que para o primeiro grupo nenhuma droga foi administrada (n=8), para o segundo grupo foi administrado por via oral 20 mg/Kg/dia de espironolactona (n=10) e para o terceiro, 7 mg/Kg/dia de amilorida (n=12). O peso e a pressão sistólica foram monitorados semanalmente. Coletas de urina (durante 24 h) e sangue foram realizadas em 3 períodos distintos: antes do procedimento cirúrgico; na 2° semana após a cirurgia (antes do início do tratamento) e na 6° semana após a cirurgia (após o término do tratamento). As amostras foram utilizadas para análise de creatinina, osmolalidade, sódio, potássio e albuminúria. Ao final do experimento, os rins foram perfundidos e pesados. Análise histológica para avaliar a extensão das alterações tubulointersticiais foi realizada. Além disso, marcadores de inflamação (ED-1 e p-JNK), de produção de matriz extracelular (fibronectina), de miofibroblastos (-actina de músculo liso) e de transdiferenciação tubular (vimentina) na região tubulointersticial cortical e de lesão nos podócitos (desmina) foram avaliados. O tratamento com espironolactona foi capaz de atenuar o aumento na excreção de albumina, o aumento na concentração plasmática de creatinina e a redução na depuração de creatinina. No rim clipado dos ratos 2R-1C, as lesões tubulointersticias e podocitárias, demonstradas pelos marcadores estudados, foram discretas e a terapia com espironolactona ou amilorida não foi capaz de minimizá-las. Por outro lado, no rim não clipado, a administração de espironolactona atenuou o aumento de matriz extracelular e a lesão nos podócitos. Os efeitos benéficos da espironolactona ocorreram independentes da redução na pressão sanguínea e podem ser em parte, dependentes do bloqueio do canal epitelial de sódio (ENaC). Tais efeitos trazem perspectiva para espironolactona como uma ferramenta terapêutica a ser explorada em pacientes com estenose de artéria renal. / Aldosterone is involved in the progression of renal disease in experimental models and clinical trials. Considering that the model of renovascular hypertension 2 kidney-1 clip (2K-1C) is characterized by a high activity of the renin-angiotensin-aldosterone system, the objective of this study was to assess the role of aldosterone in renal injury in this model by blocking the mineralocorticoid receptor (MR) with spironolactone. Male Wistar rats were submitted to surgery to place a silver clip on the left renal artery and after two weeks of the development of 2K-1C renovascular hypertension they were divided into three groups. The first group was administered no drug (n=8), in the second group spironolactone 20 mg/kg/day was given orally (n=10) and the third group received amiloride 7 mg/kg/day (n=12). Body weight and systolic blood pressure were monitored weekly. Samples of urine (collected for 24 h) and blood were performed in 3 distinct periods: before surgery; 2 weeks after surgery (before treatment) and 6 weeks after surgery (after treatment). The samples were used to analyze creatinine, osmolality, sodium, potassium and albuminuria. At the end of the experiment, the kidneys were perfused and weighed. Histological analysis to assess the extent of tubulointerstitial changes was performed. Additionally, markers of inflammation (ED-1 and p-JNK), production of extracellular matrix (fibronectin), myofibroblasts (-smooth muscle actin) and tubular transdifferentiation (vimentin) in the area of tubulointerstitial cortical and injury in podocytes (desmin) were evaluated. Treatment with spironolactone was able to attenuate the increase in albumin excretion, the increase in plasma concentration of creatinine and the reduction in creatinine clearance. In the clipped kidney, tubulointerstitial and podocytes injuries, demonstrated by markers studied, were discrete and therapy with spironolactone or amiloride was not able to minimize them. However, in the non-clipped kidney, administration of spironolactone attenuated the increase of extracellular matrix and podocyte injury. The beneficial effects of spironolactone occurred independent of the reduction blood pressure and can be partly dependent of epithelial sodium channel (ENaC) blockade. These effects bring perspective to espironolactone as a therapeutic tool to be explored in patients with renal artery stenosis.

Despite the number of therapeutic interventions currently available for treating hypertension, approximately one-third of adult patients in the United States currently being treated remain hypertensive (43). As the number of hypertensive patients continues to grow, it is becoming increasingly important to investigate the different types of hypertension in order to have a greater understanding of the pathogenesis and identify potential targets for treatment. Neurogenic hypertension refers to hypertension resulting from a centrally mediated mechanism, likely involving a sustained increase in sympathetic nervous system activity. The renin-angiotensin aldosterone system (RAAS) is a physiological cascade responsible for restoring blood pressure when it drops. The rate-limiting step involves the enzyme renin. Although there is evidence of local RAAS activity in the brain, expression of renin in the brain is very low (125). The (pro)renin receptor ((P)RR) is able to bind and activate both renin and (pro)renin. Because the (P)RR and (pro)renin expression is high in the brain, it is possible that local RAAS activity is orchestrated by the (P)RR. In this study, we investigated if neuroinflammatory conditions could foster an environment that would allow for a rise in sympathetic nervous system activity (SNA) resulting from brain RAAS activity and the (P)RR. By treating neuronal cell cultures with proinflammatory cytokines, an anti-inflammatory agent, and (pro)renin, we explored any changes or differences in mRNA expression levels. Additionally, the effects of antioxidants were investigated. The results of this study showed that cells lacking antioxidants were more vulnerable to cellular stress and inflammation in the presence of increased (pro)renin. Proinflammatory stress was correlated with increased mRNA expression of proinflammatory and immune system regulatory genes in addition to increased expression of angiotensin II type I receptor, a vital component of RAAS. This could indicate that neuroinflammatory stress can be exacerbated and contribute to increased RAAS activity in the brain mediated by the (P)RR.

Alors que l’entrée SOC (store-operated Ca2+ entry) portée par les canaux calciques TRPCs (transient receptor potential canonical) et Orai1 est essentielle dans les cellules non-excitables, son rôle physiologique dans les cardiomyocytes adultes reste à élucider. Néanmoins, il est largement admis qu’une entrée SOC exacerbée dépendante des canaux TRPCs et de la protéine régulatrice STIM1 participe à la pathogenèse de l’hypertrophie et de l’insuffisance cardiaque (IC) par induction de voies pro-hypertrophiques telles que la CaMKII (Ca2+/calmoduline-dépendante kinase II ) et la calcineurine (CaN)/NFAT (Nuclear factor of activated T-cells). Au contraire, une inhibition fonctionnelle ou une extinction génique des canaux TRPCs et de la protéine STIM1 serait cardioprotectrice contre le stress hypertrophique. Cependant, le rôle physiopathologique des canaux calciques Orai1 dans le cœur reste, à ce jour, méconnu et débattu puisque son extinction in vitro présente un effet bénéfique contre l’hypertrophie des cardiomyocytes alors que son extinction in vivo présente des effets délétères avec le développement d’une cardiomyopathie dilatée. De plus amples investigations quant au rôle d’Orai1 dans la physiopathologie cardiaque apparaissent donc primordiales. De ce fait, les objectifs de ma thèse sont d’explorer le rôle de la signalisation calcique dépendante d’Orai1 dans le cœur dans des conditions physiologiques et pathologiques grâce à un modèle de souris transgéniques exprimant un mutant non fonctionnel d’Orai1, spécifiquement dans le cœur (dn-Orai1R91W/tTa) et un inhibiteur pharmacologique sélectif, le JPIII. Tout d’abord, nous montrons que les souris dn-Orai1R91W/tTa présentent une fonction cardiaque normale et une homéostasie calcique impliquée dans le couplage excitation-contraction conservée suggérant qu’Orai1 n’a pas de rôle majeur dans le coeur adulte en condition physiologique. Cependant, nous avons démontré une augmentation de l’expression et de l’activité d’Orai1 dans un modèle murin d’hypertrophie cardiaque induite par surcharge de pression, qui serait délétère pour la fonction ventriculaire. Au contraire, l’inhibition fonctionnelle d’Orai1 par manipulation génétique ou par l’outil pharmacologique (JPIII) semble protéger le coeur des dysfonctions ventriculaires au cours de l’hypertrophie. Cet effet bénéfique passerait par une restauration de l’homéostasie calcique et notamment par un maintien de l’expression de la pompe ATPase SERCA2a. Nous avons également mis en évidence que la voie de l’aldostérone/récepteurs aux minéralocorticoïdes modulait l’expression des canaux TRPC1, -C4, -C5 et notamment Orai1 via la protéine SGK1 (Serum and Glucocorticoid-regulated Kinase 1) dans les cardiomyocytes ventriculaires de rat nouveaux-nés. L’activation de cette voie de signalisation pourrait être à l’origine de la surexpression des canaux TRPCs/Orai1 retrouvée au cours de l’hypertrophie cardiaque. Ces travaux décrivent donc Orai1 comme une cible thérapeutique potentielle dans le traitement de l’hypertrophie cardiaque et de l’IC. / While the SOCE (store-operated Ca2+ entry), carried by TRPCs (transient receptor potential canonical) and Orai1 channels, is essential in non-excitable cells, its physiological role in adult cardiomyocytes remains elusive. Nevertheless, it is well established that exacerbated TRPCs/STIM1-dependent Ca2+ entry participates in the pathogenesis of hypertrophy and heart failure (HF) via the induction of pro-hypertrophic signaling pathways, such as CaMKII (Ca2+/calmodulin-kinase II) and calcineurin (CaN)/ NFAT (nuclear factor of activated T-cells). By contrast, functional inhibition or gene silencing of TRPCs and STIM1 is cardioprotective against hypertrophic insults. As for Orai1 Ca2+ channels, their pathophysiological roles in the heart remain unknown and under debate, since in vitro Orai1 silencing has a beneficial effect against cardiomyocyte hypertrophy, whereas in vivo silencing has deleterious effects with the development of dilated cardiomyopathy. Further investigations are necessary to determine the pathophysiological role of Orai1 in the heart. My thesis objectives are to explore the role of Orai1-dependent Ca2+ signaling in the heart under physiological and pathological conditions using a transgenic mouse model expressing a non functional mutant of Orai1, specifically in the heart (dn-Orai1R91W/tTa) and a selective pharmacological inhibitor, JPIII. First, we showed that dn-Orai1R91W/tTa mice have normal cardiac function and conserved Ca2+ homeostasis involved in the excitation-contraction coupling suggesting that Orai1 is not instrumental in regulating cardiac function under physiological conditions. However, we demonstrated an increased Orai1 expression and activity in a mouse model of cardiac hypertrophy induced by pressure overload, which is a maladaptive alteration involved in pathological ventricular dysfunction. By contrast, functional inhibition of Orai1 by genetic manipulation or by the pharmacological tool (JPIII) protects the heart from ventricular dysfunction after pressure overload-induced cardiac hypertrophy. This beneficial effect is related to a restoration of Ca2+ homeostasis and more specifically, is due to preserved ATPase SERCA2a pump expression. We also showed that the aldosterone/mineralocorticoid receptor signaling pathway modulates the expression of TRPC1, -C4, -C5 channels and also the Orai1 channels expression via the SGK1 (Serum and Glucocorticoid-regulated Kinase 1) protein, in neonatal rat ventricular cardiomyocytes. The activation of this signaling pathway could be the cause of the TRPCs/Orai1 channels overexpression found during cardiac hypertrophy. In conclusion, our studies highlighted that Orai1 Ca2+ channels could constitute potential therapeutic target in the treatment of cardiac hypertrophy and HF.

京都大学 / 0048 / 新制・課程博士 / 博士(薬科学) / 甲第18924号 / 薬科博第38号 / 新制||薬||5(附属図書館) / 31875 / 京都大学大学院薬学研究科医薬創成情報科学専攻 / (主査)教授 岡村 均, 教授 中山 和久, 教授 竹島 浩 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DGAM

The prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly reached pandemic proportions, and knowledge about this virus and coronavirus disease 2019 (COVID-19) has expanded rapidly. This review focuses primarily on mechanisms that contribute to acute cardiac injury and dysfunction, which are common in patients with severe disease. The etiology of cardiac injury is multifactorial, and the extent is likely enhanced by pre-existing cardiovascular disease. Disruption of homeostatic mechanisms secondary to pulmonary pathology ranks high on the list, and there is growing evidence that direct infection of cardiac cells can occur. Angiotensin converting enzyme 2 (ACE2) plays a central role in COVID-19 and is a necessary receptor for viral entry into human cells. ACE2 normally not only eliminates angiotensin II (Ang II) by converting it to Ang (1-7), but also elicits a beneficial response profile counteracting that of Ang II. Molecular analyses of single nuclei from human hearts have shown that ACE2 is most highly expressed by pericytes. Given the important roles that pericytes have in the microvasculature, infection of these cells could compromise myocardial supply to meet metabolic demand. Furthermore, ACE2 activity is crucial for opposing adverse effects of locally generated Ang II, so virus-mediated internalization of ACE2 could exacerbate pathology by this mechanism. While the role of cardiac pericytes in acute heart injury by SARS-CoV-2 requires investigation, expression of ACE2 by these cells has broader implications for cardiac pathophysiology.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第25000号 / 医博第5034号 / 新制||医||1070(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 長船 健二, 教授 尾野 亘, 教授 江藤 浩之 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Congestive heart failure is commonly treated with a low sodium diet and diuretic. The purpose of this treatment is the reduction of preload, or blood volume presented to the diseased cardiac muscle. The purpose of this study was to assess the roles of dietary sodium and furosemide on cardiac function, plasma electrolyte concentrations, and the renin-angiotensin-aldosterone system, in healthy canines. Twenty mixed-breed canines were allotted to one of four groups, Group I - Dogs fed low sodium diet (0.08% sodium), Group II - Dogs fed high sodium diet (1.0% sodium), Group III - Dogs fed low sodium (0.08%) and treated with furosemide (2 mg/kg orally (PO) every twelve hours (BID)), and Group IV - Dogs fed high sodium (1.0%) and furosemide ( 2 mg/kg PO BID). Cardiac function was assessed via echocardiography on days 0, 21,and 53. Plasma electrolyte concentrations were measured on days 0, 21, and 35. Activation of the renin-angiotensin-aldosterone system was evaluated on days 0, 21, 35, and 53. Low and high sodium diet with and without furosemide treatment did not alter cardiac function, plasma sodium, or plasma potassium concentrations. However, furosemide treatment combined with a low sodium diet resulted in the lowest plasma chloride concentrations, on days 21 and 35 (p<0.05). Furthermore, furosemide treatment resulted in significant alterations in the renin-angiotensin-aldosterone system, on days 21, 35, and 53, (p < 0.0001). Furosemide treatment significantly increased renin activity and aldosterone concentration. The interaction between furosemide and the low sodium diet yielded a greater increase in plasma renin activity and plasma aldosterone concentrations than furosemide administration with the high sodium diet. These results suggest direct activation of the renin-angiotensin-aldosterone system by furosemide. Future research is warranted in congestive heart failure subjects, due to the adverse affects of decreased plasma chloride concentrations and activation of the renin-angiotensin-aldosterone system. / Master of Science

Thesis (MScMedSc (Biomedical Sciences. Molecular Biology and Human Genetics))--University of Stellenbosch, 2009. / Hypertrophic cardiomyopathy (HCM), an inherited primary cardiac disorder mostly caused by defective sarcomeric proteins, is considered a model for studying left ventricular hypertrophy (LVH) in the absence of increased external loading conditions. The disease manifests extreme variability in the degree and pattern of LVH, even in HCM patients with the same causal mutation. The clinical phenotype of HCM can therefore be viewed as a product of the effect of sarcomere dysfunction and of additional genetic modifiers. Components of the renin-angiotensin-aldosterone system (RAAS) are plausible candidate modifiers because of their effect on blood pressure and their direct hypertrophic effect on cardiomyocytes. The present study investigated genes encoding components of the RAAS for association with cardiac hypertrophy traits, in 353 individuals comprised of genetically and echocardiographically affected and unaffected family members, belonging to 22 HCM families with HCM founder mutations by employing a multi-SNP approach with TaqMan allelic discrimination technology. Gene-gene interaction analysis was also performed to investigate the effect of epistasis on hypertrophy. Candidate genes for analysis included the angiotensin II type 2 receptor (AT2 receptor), renin, renin-binding protein (RnBP), the (pro)renin receptor, the mineralocorticoid receptor as well as genes encoding subunits of the epithelial sodium channels (ENaC) and Na+/K+-ATPase that showed evidence for cardiac expression. The present study demonstrates for the first time that variations in the renin and RnBP genes play a role in modulating hypertrophy in HCM, independent of blood pressure and confirms the involvement of the AT2 receptor in hypertrophy in HCM. Additionally we report an association between Na+/K+-ATPase α1- and β1-subunits as well as the ENaC α- and β-subunits and hypertrophy. Significant evidence for epistasis was found between renin and downstream RAAS effectors, suggesting a complex interplay between these RAAS variants and the hypertrophic phenotype in HCM. The identification of such modifiers for HCM may offer novel targets for hypertrophy research and ultimately antihypertrophic therapy.

A Abstinência ao Etanol (AE) é uma complicação de curta duração desenvolvida após a interrupção parcial ou total do consumo crônico de etanol. Alguns dos sintomas descritos incluem: aumento transitório da pressão arterial, alteração da resistência vascular periférica e alterações comportamentais; entretanto, os mecanismos envolvidos nessas respostas continuam elusivos. O objetivo desse estudo foi o de investigar os efeitos da abstinência ao etanol sobre o sistema renina-angiotensina-aldosterona (SRAA) e a função vascular. Ratos Wistar (250g) foram divididos em 3 grupos: Controle (CTR): os animais receberam água ad libitum por 23 dias; Etanol (EtOH): o tratamento crônico com etanol foi iniciado com uma solução de etanol 3% (vol./vol.), sendo gradualmente aumentada a cada três dias para 6% (4º dia) e 9% (7º dia em diante), mantendo-se esta concentração até o 21° dia; Abstinência ao Etanol (AE): os animais foram tratados da mesma maneira que o grupo EtOH até o 20º dia, neste dia a solução de etanol 9% foi retirada e retornada no dia seguinte (21º dia) por apenas 2h; após o término deste período, os animais receberam água até o dia do teste (23º dia), garantindo assim, o quadro de abstinência por 48h. Para avaliar o comportamento, os animais foram testados no Labirinto em Cruz Elevado (LCE). A pressão arterial foi medida por pletismografia de cauda. Foram avaliados os níveis plasmáticos de: a) etanol por cromatografia gasosa; b) corticosterona (CORT), angiotensina I e II (ANGI e II), vasopressina (AVP), ocitocina e peptídeo natriurético atrial (ANP) por radioimunoensaio; c) aldosterona (ALDO), renina (REN) e espécies reativas de oxigênio ao ácido tiobarbitúrico (TBARS) por ELISA; atividade plasmática da enzima conversora de angiotensina por fluorímetria; d) atividade da NAD(P)H-oxidase em aorta e leito mesentérico pelo método de quimioluminescência da lucigenina; d) de sódio (Na+ ) por fotometria de chama; e) osmolaridade foi medida pelo abaixamento do ponto de congelamento da água. Foi realizada avaliação da reatividade vascular em aorta isolada para angiotensina II (ANG II), fenilefrina, cloreto de potássio, acetilcolina e nitroprussiato de sódio (NPS). A abstinência ao etanol promoveu diminuição significativa da porcentagem de entrada e tempo despendido nos braços abertos do LCE; além disso, houve aumento da concentração plasmática de corticosterona. Em conjunto estes resultados mostram o efeito ansiogênico da abstinência ao etanol. A abstinência ao etanol também promoveu aumento da pressão arterial sistólica e média. Houve aumento do estresse oxidativo sistêmico e tecidual. Em relação ao balanço hidroeletrolítico, não foi encontrada nenhuma alteração induzida pela abstinência ao etanol. A abstinência ao etanol induziu alterações vasculares independentes de endotélio representada por diminuição da contração para ANG II, fenilefrina e KCl e aumento do relaxamento para o nitroprussiato de sódio. A partir destes resultados podemos concluir que a abstinência ao etanol induz ansiedade, estimula o SRAA, induz hipertensão e estresse oxidativo e altera a função vascular de maneira independente de endotélio. / Ethanol withdrawal is a short-term complication developed after partial or total interruption of chronic ethanol consumption. Some of the symptoms described include: transient increase in blood pressure, peripheral vascular resistance changes and behavioral changes, however, the mechanisms involved in these responses remain elusive. The aim of this study was to investigate the effects of ethanol withdrawal on the renin-angiotensin-aldosterone system (RAAS) and vascular function. With this purpose, male Wistar rats (250g) were divided into 3 groups: control (CTR): animals received water ad libitum for 23 days, ethanol (EtOH): chronic treatment with ethanol was started with an ethanol solution 3% (vol. / vol.) being gradually increased every three days to 6% (day 4) and 9% (day 7 onwards), being this concentration maintained until day 21; Ethanol abstinence (EA): animals were treated in the same way of the EtOH group until day 20. Then, ethanol solution 9% was removed and returned the next day (day 21) for 2h. After the end of this period, the animals received water until day 23, ensuring abstinence for 48 hours. Animals were tested on the Elevated Plus Maze (EPM). Blood pressure was measured by tail plethysmography. Plasma levels of: a) ethanol were determined by gas chromatography, b) corticosterone (CORT), angiotensin I and II (ANGI and II), vasopressin (AVP), oxytocin, and atrial natriuretic peptide (ANP) by radioimmunoassay; c ) aldosterone (ALDO), plasma activity of angiotensin converting enzyme by fluorimetry; renin (REN) and thiobarbituric acid reactive substances (TBARS) by ELISA; d) activity of NAD (P)H in the aorta and mesenteric arterial bed by lucigenin chemiluminescence assay; d) sodium (Na+ ) by photometry; e) osmolarity was measured by the lowering of the freezing point of water. Vascular reactivity of isolated aorta to angiotensin II (ANG II), phenylephrine, KCl, acetylcholine, and sodium nitroprusside (SNP) was evaluated. Abstinence to ethanol induced a significant reduction in the percentage of entries and time spent in the open arms of the EPM. Increased corticosterone plasma levels were also detected in animals from the EA group. Together these findings suggest that abstinence to ethanol induces an anxiogenic-like effect. Abstinence to ethanol induced an increase in plasma ANG II with no changes on ANG I, renin or aldosterone levels. The levels of ANG I and ANG II in the aorta and mesenteric arterial bed were not altered in animals from the EA group. Abstinence to ethanol also induced increase in systolic blood pressure and mean arterial blood pressure. Abstinence to ethanol increased systemic oxidative stress and the vascular generation of superoxide anion. No change in the fluid balance was detected in animals from the EA group. In endothelium-denuded, but not intact aortic rings, abstinence to ethanol decreased the contraction induced by ANG II, phenylephrine and KCl. Increased NPS-induced relaxation was also observed in rings from EA animals. We conclude that ethanol withdrawal: a) induces anxiety; b) stimulates the systemic RAAS; c) increases blood pressure; d) induces systemic and vascular oxidative stress; e) alters the vascular function in an endothelium-independent manner.